Van ECK Associates Corp Sells Shares of Halozyme Therapeutics, Inc

August 12, 2023

Categories: BiotechnologyTags: , , Views: 30

☀️Trending News

Van ECK Associates Corp recently sold shares of Halozyme Therapeutics ($NASDAQ:HALO), Inc. at Defense World. Halozyme Therapeutics is an innovative biopharmaceutical company that is focused on developing and commercializing novel therapies that utilize biosynthetic recombinant enzyme technologies. The company primarily uses its patented Enhanze Technology to develop treatments for cancer and other serious diseases. Halozyme’s Enhanze Technology focuses on increasing the rate of absorption for drugs administered intravenously or subcutaneously.

With this technology, Halozyme is able to create new therapies that reach target tissues by rapidly permeating into the bloodstream. Van ECK Associates Corp’s decision to sell shares of Halozyme Therapeutics, Inc. at Defense World indicates that the company believes in the potential of Halozyme’s technology and products. Investors should take note of this momentous sale and research Halozyme further to decide if it is a viable investment opportunity.

Stock Price

On Monday, Van ECK Associates Corp sold a portion of its shares in Halozyme Therapeutics, Inc. Following the selloff, the stock opened at $42.6 and eventually closed at $42.0, down 0.9% from its previous closing price of $42.4. This slight decrease in the stock price does not appear to be indicative of any worsening in the company’s financials or outlook, and the decision to sell appears to be purely for portfolio management reasons. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Halozyme Therapeutics. More…

    Total Revenues Net Income Net Margin
    773.65 233.71 29.7%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Halozyme Therapeutics. More…

    Operations Investing Financing
    305.89 -7.92 -168.24
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Halozyme Therapeutics. More…

    Total Assets Total Liabilities Book Value Per Share
    1.81k 1.66k 1.15
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Halozyme Therapeutics are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    62.4% 21.2% 40.2%
    FCF Margin ROE ROA
    37.8% 179.3% 10.7%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    GoodWhale performed an analysis of HALOZYME THERAPEUTICS using our Star Chart system and the results indicate that the company has an intermediate health score of 6 out of 10. This means that the company may be able to pay off its debt and fund future operations. The analysis showed that HALOZYME THERAPEUTICS is strong in growth, profitability, but weak in asset and dividends. We classified the company as a ‘gorilla’ which is a type of company that achieved stable and high revenue or earning growth due to its strong competitive advantage. Considering these results, GoodWhale recommends that investors who are interested in HALOZYME THERAPEUTICS should focus on the company’s growth and profitability, while also keeping an eye on its asset and dividend situation. We believe that investors who are looking for a stable long-term investment should strongly consider HALOZYME THERAPEUTICS. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The Company’s enzyme-based product candidates target the tumor microenvironment, enabling the delivery of cancer drugs directly to the site of the tumor. Halozyme has four product candidates in clinical development, PEGPH20, Hylenex, HALO-102 and HALO-201. Keymed Biosciences Inc, Verona Pharma PLC, Xencor Inc are Halozyme’s competitors in the biopharmaceutical market.

    – Keymed Biosciences Inc ($SEHK:02162)

    Keymed Biosciences Inc is a biopharmaceutical company that focuses on the development and commercialization of novel therapeutics for the treatment of cancer and other serious diseases. The company’s market cap is 12.95B as of 2022 and has a ROE of -4.34%. Keymed Biosciences Inc’s products are designed to target key drivers of disease progression and to provide patients with new treatment options. The company’s lead product, KEY-184, is a first-in-class, orally-available small molecule inhibitor of the MDM2 oncoprotein.

    – Verona Pharma PLC ($NASDAQ:VRNA)

    Verona Pharma PLC is a pharmaceutical company that focuses on the development of drugs for the treatment of respiratory diseases. The company has a market cap of 790.27M as of 2022 and a Return on Equity of -28.69%. Verona Pharma PLC is headquartered in London, United Kingdom.

    – Xencor Inc ($NASDAQ:XNCR)

    Xencor Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. The company’s market cap as of 2022 is 1.64B with a ROE of 4.05%. Xencor is currently working on several clinical-stage programs including XmAb5871 for the treatment of B-cell malignancies, autoimmune diseases, and asthma.


    Van ECK Associates Corp recently sold shares of Halozyme Therapeutics, Inc., a biotechnology company focused on drug delivery technologies. Investment analysis of the company has indicated that its stock has the potential to be a solid long-term investment. The company’s technology is based on recombinant human hyaluronidase, an enzyme that helps deliver drugs through the body’s tissues and into the bloodstream. In addition to its potential as a drug delivery system, Halozyme has also developed a biosimilar program for the treatment of cancer and auto-immune diseases. Investors should be aware that Halozyme carries some risk due to its limited operating history and lack of revenue.

    However, with its diverse product portfolio and promising pipeline, Halozyme has the potential to be a long-term growth story in the healthcare industry.

    Recent Posts

    Leave a Comment